Opportunities for CAR-T Cell Immunotherapy in HIV Cure
Campos-Gonzalez, Gerard (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Martinez-Picado, Javier (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Velasco-Hernández, Talia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Salgado, Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)

Date:	2023
Abstract:	Chimeric antigen receptor (CAR) technology is having a huge impact in the blood malignancy field and is becoming a well-established therapy for many types of leukaemia. In recent decades, efforts have been made to demonstrate that CAR-T cells have potential as a therapy to achieve a sterilizing cure for human immunodeficiency virus (HIV) infection. However, translation of this technology to the HIV scenario has not been easy, as many challenges have appeared along the way that hinder the consolidation of CAR-T cells as a putative therapy. Here, we review the origin and development of CAR-T cells, describe the advantages of CAR-T cell therapy in comparison with other therapies, and describe the major obstacles currently faced regarding application of this technology in the HIV field, specifically, viral escape, CAR-T cell infectivity, and accessibility to hidden reservoirs. Nonetheless, promising results in successfully tackling some of these issues that have been obtained in clinical trials suggest a bright future for CAR-T cells as a consolidated therapy.
Grants:	Agencia Estatal de Investigación PID2020-115931RA-I00 Agencia Estatal de Investigación PID2019-109870RB-I00 European Commission 101057100 European Commission 101095606
Note:	Altres ajuts: Fundació La Marató de TV3 (202130-30-31-32); Generalitat de Valencia (PROMETEO/2021/036)
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Ressenya ; recerca ; Versió publicada
Published in:	Viruses, Vol. 15 Núm. 3 (march 2023) , ISSN 1999-4915

DOI: 10.3390/v15030789
PMID: 36992496

13 p, 2.2 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Josep Carreras Leukaemia Research Institute
Articles > Research articles
Articles > Published articles
Articles > Reviews